LINC00671 inhibits renal cell cancer progression via regulating miR-221-5p/SOCS1 axis

Gang Jin1*, Haiyan Mi2*, Yunfei Ye3*, Qi Yao4, Lei Yuan5*, Xiaoxiong Wu6

1Department of Urology Surgery, The No. 1 People’s Hospital of Pinghu Community, Pinghu 314200, China; 2Department of Nephrology, Affiliated Nashua Hospital, University of South China, Hengyang 421002, China; 3Department of Radiation Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, China; 4Department of Outpatient, The No. 1 People’s Hospital of Pinghu Community, Pinghu 314200, China; 5The First Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China; 6Second Department of Oncology, Seventh People’s Hospital of Shanghai University of TCM, Shanghai 200037, China. *Equal contributors.

Received April 16, 2020; Accepted March 2, 2021; Epub July 15, 2021; Published July 30, 2021

Abstract: Background: Long non-coding RNA (IncRNA) has gradually received widespread attention due to its role in regulating tumor progression. However, in renal cell cancer (RCC), the exact function of IncRNA LINC00671 remains uncertain. Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was utilized for detecting LINC00671 and miR-221-5p expressions in RCC tissues and cell lines. Western blotting technique was utilized for detecting the expressions of epithelial-mesenchymal transition (EMT)-associated proteins (E-cadherin and N-cadherin) and suppressor of cytokine signaling 1 (SOCS1). The correlation between clinicopathological features and LINC00671 expression was also evaluated. RCC cell multiplication, migration and invasion were measured by CCK-8, EdU and Transwell assays, respectively. The targeted relationships between LINC00671 as well as the SOCS1 3’UTR and miR-221-5p were verified by RNA immunoprecipitation (RIP) and luciferase reporter gene assay. Results: LINC00671 expression in RCC tissues and cells was significantly reduced. Patients with low LINC00671 expression had relatively shorter disease-free survival and overall survival. Moreover, LINC00671 expression was linked to lymph node metastasis, tumor stage, and tumor size. In Caki-1 and 769-P cell lines, LINC00671 overexpression restrained the multiplication, migration, invasion, as well as the EMT process of RCC cells in vitro. In terms of mechanism, miR-221-5p was identified as a target of LINC00671, and LINC00671 could up-regulate SOCS1 by repressing miR-221-5p. Conclusion: LINC00671 regulates the miR-221-5p/SOCS1 axis as a tumor suppressor in RCC.

Keywords: RCC, LINC00671, Mir-221-5p, SOCS1

Introduction

Renal cell cancer (RCC) originates from renal tubular epithelial cells [1]. Statistically there emerge nearly 295,000 new RCC cases globally every year, with about 134,000 cases killed [2]. RCCs have four subtypes: chromophobe RCC, papillary RCC, clear cell RCC (ccRCC) and renal oncocytoma [3]. A majority of the patients with RCC are insensitive to radiotherapy and chemotherapy, and the prognosis outcome of patients with metastatic RCC remains unsatisfactory, and their five-year survival rate is only about 10% [4, 5]. Hence, to explore the effective therapy targets for RCC, it is imperative to figure out the molecular mechanism underlying RCC progression.

Known as a category of transcripts, long non-coding RNAs (IncRNAs) are characterized by over 200 nucleotides and having no protein-coding function [6]. A growing number of studies in recent years show that IncRNAs partake in different biological processes, i.e., cell growth, migration, apoptosis, invasion, autophagy, etc., and is pivotal in the progression of human cancers, such as RCC [7-11]. For instance, LIN00673 facilitates cancer cell proliferation and invasion via suppressing KLF4 expression through the interaction with DNMT1.
LINC00671 and RCC

Table 1. Correlation of LINC00671 expression with clinicopathologic characteristics of RCC patients

<table>
<thead>
<tr>
<th>Clinicopathologic features</th>
<th>Cases</th>
<th>LINC00671 expression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=53</td>
<td>High (n=26)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 60</td>
<td>36</td>
<td>16</td>
</tr>
<tr>
<td>≥ 60</td>
<td>17</td>
<td>10</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>38</td>
<td>21</td>
</tr>
<tr>
<td>Female</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>Fuhrman grade</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 1+2</td>
<td>41</td>
<td>22</td>
</tr>
<tr>
<td>Grade 3+4</td>
<td>12</td>
<td>4</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 7</td>
<td>28</td>
<td>18</td>
</tr>
<tr>
<td>&gt; 7</td>
<td>25</td>
<td>8</td>
</tr>
<tr>
<td>Tumor stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pT1</td>
<td>30</td>
<td>10</td>
</tr>
<tr>
<td>pT1+T32</td>
<td>23</td>
<td>16</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>21</td>
<td>6</td>
</tr>
<tr>
<td>No</td>
<td>32</td>
<td>21</td>
</tr>
</tbody>
</table>

*P < 0.05 and **P < 0.01 were considered to be statistically significant.

and EZH2 in gastric cancer [9]. LINC00346 promotes the pathogenesis of pancreatic ductal adenocarcinoma by activating c-Myc [10]. In RCC, the over-expression of LINC-PINT is associated with unfavorable prognosis of the patients, and its over-expression induces cell cycle progression, promotes ccRCC cell proliferation, and inhibits apoptosis [11]. In RCC, IncRNA RP11-436H11.5 is highly expressed, and it enhances BCL-W expression through modulating miR-335-5p expression, and enhances the malignant biological behaviors of RCC cells [12]. A recent study shows that LINC00671 is a novel prognostic marker for pancreatic cancer (PC) and plays a cancer-suppressing role in PC [13]. Nonetheless, LINC00671’s function in RCC progression is yet to be studied.

Recognized as a category of highly conserved endogenous non-coding RNA, microRNAs (miRNAs) contain 18-25 nucleotides. It binds directly to the target mRNA 3'-untranslated region (3'-UTR), triggering mRNA translation inhibition and degradation [14]. The studies in recent have shown that multiple miRNAs contribute to regulating RCC progression [15, 16]. For instance, miR-21 facilitates RCC cells’ proliferation and reduces their apoptosis by activating the mTOR-STAT3 signaling pathway [17]. MiR-181a overexpression boosts cell multiplication and cell cycle progression, and down-regulates KLF6 in ccRCC cells to inhibit apoptosis [18]. MiR-221-5p plays a tumor-suppressing role in colorectal carcinoma and prostate carcinoma [19-22]. In addition, miR-221-5p targets suppressor of cytokine signaling 1 (SOCS1) in prostate cancer cells, and regulates the MAPK/ERK signaling pathway [22].

This work was intended to explore LINC00671’s functions and potential mechanisms in RCC. It was discovered that LINC00671 expression was notably reduced in RCC tissues. Functional experiments showed that LINC00671 repressed RCC cells’ proliferation, migration, invasion. Mechanistically, we found that LINC00671 inhibited RCC progression via targeting miR-221-5p to enhance SOCS1 expression.

Materials and methods

Tissue sample

53 pairs of RCC samples as well as corresponding normal kidney tissue samples were acquired from patients who undergone nephrectomy in Shanghai Seventh People’s Hospital. After being frozen with liquid nitrogen, the samples were preserved at -196°C. The current study obtained the approval of the Ethics Committee of Shanghai Seventh People’s Hospital. Additionally, the patients enrolled signed an informed consent form before surgery. The patients’ clinicopathological features are summarized in Table 1.

Cell lines and cell culture

From the American Type Culture Collection (ATCC; Rockville, MD, USA), five human RCC cell lines, including 769-P, 786-O, A498, ACHN and Caki-1, and normal human renal cell line HK-2 were bought. They were incubated in...
Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen, Grand Island, NY, USA) with 100 U/ml penicillin and 0.1 mg/ml streptomycin (Hyclone, Logan, UT, USA) and 10% (v/v) heat-inactivated fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA). All cells were kept in 5% CO₂ at 37°C in an incubator.

Transfection

NC mimics and miR-221-5p mimics were bought from GenePharma Co., Ltd. (Shanghai, China). Ribobio Co., Ltd. (Guangzhou, China) provided plasmids: pcDNA3.1-LINC00671 (pc-LINC00671), pcDNA3.1-SOCS1 (pc-SOCS1), and pcDNA3.1-NC (pc-NC). The cells during logarithmic growth were collected and transferred into 6-well plates (2 × 10⁶ cells/well). 12 h later, following the manufacturer’s protocol, the miRNAs and plasmids were transfected into Caki-1 and 769-P cells with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).

Quantitative real-time polymerase chain reaction (qRT-PCR) assay

TRIzol reagent (Invitrogen, Waltham, MA, USA) was utilized for the extraction of total RNA. PrimeScript™ RT reagent kit and One Step PrimeScript miRNA cDNA synthesis kit (Takara, Dalian, China) were adopted in reverse transcription. On the Applied Biosystems 7500 detecting system (Applied Biosystems, Foster City, CA, USA), the SYBR Premix Ex Taq™ Kit (Takara, Dalian, China) was employed for conducting qRT-PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) acted as the internal reference to quantify the expressions of LINC00671 and SOCS1, and U6 functioned as the internal reference for quantifying miR-221-5p. Below are the primer sequences (F for forward; R for reverse): LINC00671: F: 5'-ATGGGAACCTGGCCACATCA-3', R: 5'-TTCTCGGCTTCTAGTCTTG-3'; SOCS1: F: 5'-CTGCGGCTTCTATGTTGGGAC-3', R: 5'-AAAAGCGCTGGAAGGCTCTCG-3'; miR-221-5p: F: 5'-ACCTGGCATACAATGTTGATTT-3', R: universal primers; U6: F: 5'-AAGAGCTGCAAGGCTCTCG-3', R: 5'-AAGAGCTGCAAGGCTCTCG-3'.

Cell counting kit-8 (CCK-8) assay

CCK-8 (Dojindo Molecular Technologies, Inc., Kyushu, Japan) was conducted for evaluating RCC cell multiplication. After transfection, cells were inoculated at 2 × 10⁶ cells/well into 96-well plates. CCK8 solution (10 μL) was loaded into each well after culturing the cells for 24, 48, 72 and 96 h, respectively. After that, these cells were cultured for another 1 h. Subsequently, the optical density (OD) at 450 nm was measured.

EdU analysis

RCC cells were inoculated into 24-well plates at 5 × 10⁵ cells/well. Subsequently, according to the instruction of EdU kit (Beyotime, Shanghai, China), each well was added with EdU solution. Then after incubation for 4 h, the cells were rinsed by PBS. 4% parafomaldehyde was utilized to fix cells. Following the addition of Apollo solution, in the dark the cells were incubated for 30 min, and the permeability of the cells was increased by the addition of 0.5% Triton X-100. Afterwards, cells were incubated with Hoechst 33342. Eventually, a fluorescence microscope was adopted for observing the cells. The EdU-positive cell rate was calculated as red fluorescence-labeled cell counts/blue fluorescence-labeled cell counts × 100%.

Transwell migration and invasion assays

RCC cell invasion and migration were examined using Transwell chambers (Corning, NY, USA). RCC cells were re-suspended in FBS-free medium, transferred into the top chamber, and medium containing 20% FBS was supplemented to the bottom chambers. For migration assay, no Matrigel was added, while a layer of Matrigel was used to cover the filter to mimic extracellular matrix in invasion assay. The Transwell chambers were kept in the incubator for 24 h, and cotton swabs were employed for wiping the cells remaining on the membrane’s upper surface. Then 95% ethanol was employed for fixing the cells and 0.5% crystal violet was employed for staining the migrated and invaded cells. After staining, PBS was used for washing membranes, and the migrated and invaded cells were counted under a microscope.

Subcellular fractionation

To determine the cellular localization of LINCO00671, the isolation of cytoplasmic and nuclear RNA from Caki-1 and 769-P cells was performed using PARIS™ Kit (Ambion, Austin, TX, USA). Then the expression of RNA in the
cytoplasmic and nuclear fraction was detected by qRT-PCR. GAPDH and U6 served as the cytoplasmic control and the nuclear control, respectively.

**RNA immunoprecipitation (RIP) analysis**

Magna RIP™ RNA-binding protein immunoprecipitation kit (Millipore, Billerica, MA, USA) was utilized for conducting RIP assay. To put it briefly, RIP buffer was utilized for lysing RCC cells. Cell extracts and magnetic beads coupled with anti-Ago2 antibody (ab32381, 1:1000, Abcam, Shanghai, China) or control IgG were incubated together. The harvested samples were subsequently processed with proteinase K, and then total RNAs were extracted for qRT-PCR analysis.

**Luciferase reporter gene assay**

The dual-luciferase reporter assay system (Promega, Madison, WI, USA) was adopted for performing luciferase reporter gene assay. The fragments of LINC00671 and SOCS1 3′-UTR mutant type (Mut) or wild type (Wt) carrying miR-221-5p binding sites, were cloned into the luciferase reporter vector pGL3 (Promega, Madison, WI, USA) to establish LINC000671-mut, LINC000671-wt, SOCS1-mut and SOCS1-wt, respectively. The above plasmids and miR-221-5p mimics or the negative control (NC mimics) were co-transfected into Caki-1 and 769-P cells, respectively, through Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The luciferase activity was detected at 48 h after transfection following the manufacturer’s instruction.

**Western blotting**

RIPA lysis buffer (Beyotime, Shanghai, China) containing protease inhibitors was utilized for total protein extraction from cells. After denaturation, 8% SDS-PAGE was utilized for separating protein samples, which were then transferred onto the PVDF membrane (Millipore, Billerica, MA, USA). After being blocked with 5% skim milk, the membranes, together with primary antibodies: anti-E-cadherin (ab40772, 1:1000, Abcam, Shanghai, China), anti-GAPDH (ab8245, 1:2000, Abcam, Shanghai, China), anti-SOCS1 (ab3691, 1:1000, Abcam, Shanghai, China), and anti-N-cadherin (ab202030, 1:1000, Abcam, Shanghai, China), were incubated at 4°C for 10 h. Next, the PVDF membranes were rinsed with TBST twice, and incubated with anti-mouse or anti-rabbit horseradish peroxidase-coupled secondary antibodies for 1 h at room temperature, followed by washing membranes three times with TBST. Finally, electrochemical luminescence (ECL) kit (Beyotime, Shanghai, China) was employed for developing the protein bands.

**Statistical analysis**

All experiments were conducted in triplicate. SPSS Statistics 19 (SPSS Inc., Chicago, IL, USA) was the statistical analysis tool in this study. The results were expressed as mean ± standard deviation (SD). Moreover, two-tailed Student’s t-test was utilized to perform the comparison between two groups, and the comparison among multiple groups was conducted with one-way ANOVA. χ² test was carried out for the determination of the correlation between LINC00671 expression and RCC patients’ clinical/pathological features. Spearman’s correlation analysis was used for evaluating the correlation between LINC00671 and miR-221-5p expression or SOCS1 expression in RCC tissues. The difference was of statistical significance when P < 0.05.

**Results**

**LINC00671 expression was reduced in RCC tissues**

Firstly, LINC00671 expression in 53 patients’ RCC samples and corresponding para-cancerous tissues was detected. The qRT-PCR displayed that LINC00671 was down-regulated in RCC tissues in comparison to para-cancerous tissues (Figure 1A). What’s more, LINC00671 expression in renal cell carcinoma (KIRC) was marked lower than HK-2 (Figure 1B). We then searched Gene Expression Profiling Interactive Analysis (GEIPA) database. The results revealed that LINC00671 expression was notably reduced in renal papillary cell carcinoma (KIRP) in comparison with normal tissues, but its expression was not changed in renal clear cell carcinoma (KIRC) (Figure 1C). Furthermore, the disease-free survival and overall survival of RCC patients with high LINC00671 expression...
LINC00671 and RCC

Figure 1. LINC00671 expression was reduced in RCC tissues and LINC00671 was associated with poor clinical outcomes. A. qRT-PCR demonstrated that LINC00671 expression was decreased in RCC samples. B. qRT-PCR implied that LINC00671 expression in five RCC cell lines (Caki-1, 769-P, ACHN, 786-O and A498) was lower than that in human normal kidney cell line HK-2. C. GEPIA RNA-Seq data suggested that in comparison to the adjacent tissues, LINC00671 expression was reduced in RCC tissues. D. GEPIA RNA-Seq data suggested that the overall survival time of patients with high LINC00671 expression in RCC was longer. E. GEPIA RNA-Seq data suggested that the disease-free survival time of patients with high LINC00671 expression in RCC was longer. F. GEPIA RNA-Seq data suggested that LINC00671 expression was decreased with the increase of RCC stage. *P < 0.05, **P < 0.01, and ***P < 0.001.

were longer than those of patients with low LINC00671 expression (Figure 1D and 1E), and the expression of LINC00671 was decreased with the increase of clinical stage (Figure 1F).

We then studied the correlation between the clinicopathological features of patients and LINC00671 expression. All subjects were divided into two groups: high (n=26) and low (n=27) LINC00671 expression groups. These findings indicated that reduced LINC00671 expression was connected with lymph node metastasis, higher clinical stage, and larger tumor size (Table 1).

LINC00671 over-expression suppressed RCC cell proliferation, migration, invasion and EMT

To explore LINC00671’s function in RCC progression, we selected Caki-1 and 769-P cells for constructing LINC00671 over-expression cell models (Figure 2A). The effects of LINC00671 over-expression on RCC cell multiplication were assessed by EdU and CCK-8 assays, and it was demonstrated that LINC00671 over-expression significantly suppressed Caki-1 and 769-P cell multiplication (Figure 2B and 2C). Furthermore, Transwell assay indicated that LINC00671 over-expression markedly inhibited Caki-1 and 769-P cell migration and invasion (Figure 2D and 2E). Subsequently, we used Western blot for detecting the expressions of EMT-related proteins and discovered that LINC00671 overexpression remarkably facilitated E-cadherin expression and inhibited N-cadherin expression in both RCC cell lines (Figure 2F).

LINC00671 serves as the miR-221-5p target gene in RCC cells

LncRNA can sponge miRNA to act as competitive endogenous RNA (ceRNA) [23]. Based on nuclear-cytoplasmic fractionation, we demonstrated that LINC00671 was located mainly in...
the cytoplasm of Caki-1 and 69-P cells, suggesting that LINC00671 could likely act as a ceRNA (Figure 3A). According to LncBase Predicted v2 database, LINC00671 had two predicted miR-221-5p binding sites (Figure 3B). It was demonstrated from qRT-PCR that miR-221-5p expression was enhanced in RCC samples (Figure 3C) and it was inversely related to LINC00671 expression (Figure 3D). Meanwhile, qRT-PCR displayed that the expression of miR-221-5p was notably reduced in Caki-1 and 69-P cells with LINC00671 overexpression (Figure 3E). Subsequently, we constructed mutated luciferase reporter vectors LINC00671-mut-1, LINC00671-mut-2, LINC00671-mut-1&2 and wild type luciferase reporter vector LINC00671-wt, and they and miR-221-5p mimics or NC mimics, were co-transfected into 769-P and Caki-1 cell lines respectively. It was discovered that the transfection of miR-221-5p mimics markedly lowered LINC00671-wt’s luciferase activity, LINC00671-mut-1 and LINC00671-mut-2, and had no significant effect on that of LINC00671-mut-1&2 (Figure 3F). RIP was utilized for validating the direct interaction between miR-221-5p and LINC00671 in RCC cells, and it was unveiled that LINC00671 and miR-221-5p were both enriched in the immunoprecipitate containing Ago2 (Figure 3G). The above results indicated that LINC00671 could targetedly inhibit miR-221-5p expression by sponging it in RCC cells.

### MiR-221-5p served as a tumor promoter in RCC cells

Next, we evaluated miR-221-5p’s functions in RCC cells. MiR-221-5p mimics were transfected into cell lines Caki-1 and 69-P respectively. qRT-PCR indicated that the miR-221-5p mimics transfection greatly up-regulated miR-221-5p expression in RCC cells (Figure 4A). EdU and CCK-8 assays indicated that miR-221-5p overexpression enhanced Caki-1 and 69-P cell proliferation (Figure 4B and 4C). Transwell assay displayed that the miR-221-5p mimics transfection facilitated Caki-1 and 69-P cell migration and invasion (Figure 4D and 4E). Additionally, it was discovered that the miR-221-5p mimics transfection increased N-cadherin expression and inhibited E-cadherin expression in both RCC cell lines (Figure 4F).

#### MiR-221-5p targeted SOCS1 and inhibits its expression

To delve into the downstream mechanism of miR-221-5p in RCC progression, TargetScan database was employed to perform bioinformatics analysis, and it was manifested that SOCS1 was a potential miR-221-5p target (Figure 5A). It was indicated by dual-luciferase reporter assay that the luciferase activity was remarkably lowered in Caki-1 and 69-P cells co-transfected with SOCS1-wt and miR-221-5p mimics, while co-transfection with miR-221-5p mimics and SOCS1-mut caused no luciferase activity change (Figure 5B). Moreover, SOCS1 expression in RCC samples was markedly higher as opposed to para-cancerous tissues (Figure 5C), and SOCS1 and LINC00671 expressions were positively correlated in RCC samples (Figure 5D). In addition, Western blot and qRT-PCR indicated that SOCS1 mRNA and protein expressions were markedly lowered in Caki-1 and 69-P cells overexpressing miR-221-5p (Figure 5E and 5F). So in conclusion, SOCS1 was the miR-221-5p direct target, and its expression can be suppressed by miR-221-5p in RCC.

#### MiR-211-5p promoted RCC progression by repressing SOCS1

To further explore whether SOCS1 mediated miR-221-5p’s biological effects on RCC cells, we transfected SOCS1 over-expression plasmids into cell lines Caki-1 and 69-P transfected with miR-221-5p mimics (Figure 6A and 6B). Subsequently, CCK-8, EdU and Transwell assays, and Western blotting were utilized for detecting RCC cell multiplication, migration,
Figure 3. miR-221-5p served as a target of LINC00671 in RCC cells. A. Subcellular localization of LINC00671 in 769-P and Caki-1 cells was performed by RNA isolation and qRT-PCR. GAPDH is the cytoplasmic control, and U6 serves as the nuclear control. B. Bioinformatics predicted two binding sites between LINC00671 and miR-221-5p. C. qRT-PCR indicated that miR-221-5p was up-regulated in RCC samples. D. Spearman’s correlation analysis was adopted to examine the correlation of LINC00671 expression with miR-221-5p in RCC samples. E. qRT-PCR displayed that miR-221-5p expression was reduced after LINC00671 is over-expressed in 769-P and Caki-1 cells. F. LINC00671-wt, LINC00671-mut-1, LINC00671-mut-2 or LINC00671-mut-1&2 was co-transfected with miR-221-5p mimics or NC mimics into 769-P and Caki-1 cell lines, and dual-luciferase reporter assay was utilized to validate the predicted binding sites. G. RIP experiment was used for evaluating the direct interaction between LINC00671 and miR-221-5p, and it indicated that LINC00671 and miR-221-5p were immunoprecipitated with anti-AGO2 antibody from lysates of 769-P and Caki-1 cells. GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; pc-NC: pcDNA3.1-NC; pc-LINC00671: pcDNA3.1-LINC00671; LINC00671-wt: LINC00671 wild type; LINC00671-mut: LINC00671 mutant type; RIP: RNA immunoprecipitation. *P < 0.05, **P < 0.01, and ***P < 0.001.
invasion and EMT, and it was suggested that SOCS1 overexpression counteracted the promoting impact of miR-221-5p over-expression on the malignant biological behaviors of RCC cells (Figure 6C-G). In conclusion, miR-221-5p promoted RCC progression by inhibiting SOCS1 expression.

**LINC00671 suppressed tumor development in RCC via miR-221-5p/SOCS1 axis**

To further clarify whether LINC00671 regulated RCC progression through the miR-221-5p/SOCS1 axis, miR-221-5p mimics were transfected into Caki-1 and 769-P cells with LINC00671 over-expression (Figure 7A). Western blot and qRT-PCR indicated that miR-221-5p over-expression dramatically reduced the expression of SOCS1 compared with RCC cells with LINC00671 (Figure 7B and 7C). Next, CCK-8, EdU and Transwell assay and Western blot revealed that miR-221-5p over-expression not only partially counteracted the effects that LINC00671 over-expression had on RCC cell multiplication, migration and invasion, but also significantly restored the EMT process (Figure 7D-H). Therefore, it was confirmed that LINC00671 inhibited RCC development through modulating the miR-221-5p/SOCS1 axis.

**Discussion**

Accumulating studies show that IncRNA contributes to tumorigenesis and cancer progression via modulating diverse key biological processes [24-27]. Many aberrantly expressed IncRNAs are reportedly related to the malignant biological behaviors of RCC cells [28, 29]. LINC00511, as a ceRNA, regulates cyclin D1 expression by sponging miR-625 in RCC to
facilitate RCC progression [30]. LncRNA ADA-MTS9-AS2 suppresses RCC development and reverses chemoresistance of RCC cells through regulating miR-27a-3p/FOXO1 expression [31].
It is found that LINC00671 is lowly expressed in PC tissues and the serum of the patients, and the survival rate of patients with high LINC00671 expression is notably improved [13]. Nevertheless, previously, the biological function and expression characteristics of LINC00671 in RCC remain unclear. The present work indicated that in RCC tissues and cell lines, LINC00671 expression was reduced. The under-expression of LINC00671 was strongly related to lymph node metastasis, higher tumor stage, and larger tumor size in patients with RCC. Importantly, the data from The Cancer Genome Atlas (TCGA) suggested, the prognosis of RCC patients with highly expressed LINC00671 was better than those with lowly expressed LINC00671. Functional experiments displayed that LINC00671 overexpression could block RCC cell multiplication, migration, invasion and EMT. Collectively, for the first time, our work suggested that LINC00671 was a novel tumor suppressor in RCC.

MiRNA can bind directly to the target mRNA 3’UTR and induce mRNA degradation or translation inhibition, thereby contributing to various pathological and physiological processes [14, 15, 32]. A lot of studies have confirmed that miRNAs are possible targets for RCC treatment [33]. The biological functions of miR-221-5p in
different cancers are distinct [19-22, 34]. In RCC, miR-221-5p is proved to be an oncogenic miRNA: its expression is enhanced in RCC tissues, and it facilitates carcinoma cell multiplication and migration, and suppresses apoptosis in 786-O and ACHN cell lines [34]. This work also displayed that miR-221-5p was abnormally up-regulated in RCC tissues, and its mimics promoted the malignant biological behaviors of other two RCC cell lines Caki-1 and 69-P, which are consistent with the previous report [34]. Additionally, in this work, we predicted and verified that LINC00671 could targetedly suppress miR-221-5p expression, and this partly explained the mechanism by which miR-221-5p was up-regulated in RCC.

SOCS1 is a key inhibitor of MAPK/ERK signal transduction, and it contributes to inhibiting cell proliferation via arresting cell cycle and promoting apoptosis [35, 36]. SOCS1 plays a tumor-suppressing role in multiple cancers, including gastric carcinoma, prostate carcinoma and multiple myeloma [37-39]. In RCC, SOCS1 is also a tumor suppressor. Ubiquitination and proteasome degradation of SOCS1 is crucial for the metastasis of RCC cells mediated by von Hippel-Lindau (VHL), and SOCS1 facilitates nuclear redistribution and K63-ubiquitylation of VHL in response to DNA double-strand breaks to maintain the high genomic instability of RCC cells [40, 41]. It is reported that miR-221-5p specifically targets SOCS1 to accelerate prostate carcinoma cell growth and migration in vivo and in vitro [22]. In this study, bioinformatics prediction was conducted, and dual-luciferase reporter assay was utilized for validating that miR-221-5p could target the 3'-UTR of SOCS1 in RCC cells. It was discovered that miR-221-5p in RCC cells could suppress SOCS1 mRNA and protein expressions, conforming to the previous report [22]. Importantly, SOCS1 was also proved to be up-regulated by LINC00671, and SOCS1 over-expression reversed the promotional impact of miR-221-5p over-expression on the malignant biological behaviors of RCC. Collectively, it was revealed that LINC00671 played a cancer-suppressing role by regulating the miR-221-5p/SOCS1 axis.

To sum up, the present work demonstrates that LINC00671 expression is markedly reduced in RCC, and that its down-regulation is closely related to unfavorable clinicopathologic characterististics and adverse prognosis. It is also confirmed that LINC00671 inhibits RCC cell multiplication, migration and invasion, and EMT process via the miR-221-5p/SOCS1 axis. Collectively, LINC00671 can function as a favorable biomarker and new treatment target for RCC.

Acknowledgements

We thank Hubei Yican Health Industry Co., Ltd. for its linguistic assistance during the preparation of this manuscript. This work was funded by Talents Training Program of the Seventh People’s Hospital, Shanghai University of Traditional Chinese Medicine (Grant No. BDX2020-01).

Disclosure of conflict of interest

None.

Address correspondence to: Lei Yuan, The First Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, No. 225, Changhai Road, Yangpu District, Shanghai 200438, China. E-mail: icbbsuse@sina.com; Xiaoxiong Wu, Second Department of Oncology, Seventh People’s Hospital of Shanghai University of TCM, No. 358, Gaoqiao Datong Road, Pudong New Area, Shanghai 200137, China. E-mail: qyln064jon@163.com

References


